Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

NCT05116007 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

SCLC, Extensive Stage

Interventions

DRUG: AK112
DRUG: Etoposide
DRUG: Carboplatin

Sponsor

Akeso